Purple Biotech (PPBT) Equity Average (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Equity Average data on file, last reported at $9.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $9.7 million, down 70.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.7 million (down 70.55% YoY), and the FY2025 annual result was $21.3 million, down 36.66% from the prior year.
• Equity Average slipped to $9.7 million in Q1 2026 per PPBT's latest filing, from $21.2 million in the prior quarter.
• Over five years, Equity Average peaked at $91.6 million in Q2 2022 and troughed at $9.7 million in Q1 2026.
• A 5-year average of $47.2 million and a median of $32.8 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average rose 25.13% in 2022, then sank 70.55% in 2026.
• A 5-year view of Equity Average shows it stood at $49.6 million in 2022, then decreased by 26.4% to $36.5 million in 2023, then decreased by 14.57% to $31.2 million in 2024, then sank by 31.91% to $21.2 million in 2025, then tumbled by 54.51% to $9.7 million in 2026.
• Business Quant data shows PPBT's Equity Average at $9.7 million in Q1 2026, $21.2 million in Q4 2025, and $32.4 million in Q3 2025.